Kocaeli Med J. 2020; 9(1): 83-88 | DOI: 10.5505/ktd.2020.64507

Anti-inflammatory and anti-fibrotic effects of ursodeoxycholic acid in streptozocin-induced diabetic rats

Ýsmail Polat Canbolat¹, Gürkan Yiðittürk², Oytun Erbaþ^3
1Department of Cardiology, Demiroðlu Bilim University, Ýstanbul, Turkey
²Department od Histology and Embryology, Muðla Sýtký Koçman University Faculty of Medicine, Muðla, Turkey
³Department of Physiology, Demiroðlu Bilim University, Ýstanbul, Turkey

INTRODUCTION: Diabetic cardiomyopathy is a consequence of free fatty acid oxidation, dysfunction in mitochondria, oxidative stress and diffuse myocardial fibrosis. We aimed to investigate the anti-inflammatory and anti-fibrotic effect of ursodeoxycholic acid in streptozocin-induced diabetic rat model.
METHODS: Male Sprague Dawley albino mature rats were divided into 3 groups: Group 1 (n=10) control group; group 2 (n=10) diabetic rats group; group 3 (n=10): diabetic rats treated with ursodeoxycholic acid group. Diabetes mellitus model was established after injection of intraperitoneal streptozocin. Histopathological and biochemical examinations were done after 4 weeks from heart tissues. Immunoexpression levels of fibronectin and TGF-β were obtained. Malondialdehyde levels were used to determine lipid peroxidation and pentraxin-3 levels were used to determine inflammation. Myocardial damage was also determined with troponin-T and pro-BNP levels.
RESULTS: Cardiac muscle cell thickness (hypertrophy), TGF-β levels, fibronectin immunoexpression malondialdehyde, pentraxin-3, troponin-T and pro-BNP levels were increased significantly in groups 2 and 3 when compared to control group. Administration of ursodeoxycholic acid significantly reduced inflammation and fibrosis in group 3 compared to group 2.
DISCUSSION AND CONCLUSION: In this experimental study, we demonstrated the anti-inflammatory and anti-fibrotic effects of UDCA on diabetic rats and it can be a good drug candidate for DM patients

Keywords: ursodeoxycholic acid, diabetic cardiomyopathy, inflammation, cardiac fibrosis

---

Ursodeoksikolik asidin streptozosin ile diyabet oluþturulmuþ farelerde kardiyomyopatideki antiinflamatuar ve anti-fibrotik etkileri

Ýsmail Polat Canbolat¹, Gürkan Yiðittürk², Oytun Erbaþ^3
1Demiroðlu Bilim Üniversitesi Týp Fakültesi, Kardiyoloji Ana Bilim Dalý, Ýstanbul
²Muðla Sýtký Koçma Üniversitesi Týp Fakültesi, Histoloji ve Embriyoloji Ana Bilim Dalý, Muðla
³Demiroðlu Bilim Üniversitesi Týp Fakültesi, Fizyoloji Ana Bilim Dalý, Ýstanbul

GÝRÝÞ ve AMAÇ: Diabetik kardiyomyopati, serbest yað aside oksidasyonu, mitokondrial disfonksiyon, oksidatif stress ve diffuz miyokardiyal fibrozise seconder olarak geliþmektedir. Bu deneysel çalýþmada, ursodeoksikolik asidin streptozocin ile tetiklenmiþ diabetik fare modelinde anti-inflamatuar ve anti-fibrotik etkilerini araþtýrmayý hedefledik.
YÖNTEM ve GEREÇLER: Sprague Dawley albino 30 eriþkin fare 3 gruba ayrýldý: Grup-1: kontrol grubu (n=10); Grup-2 (n=10) diabetik fare grubu; Grup-3 (n=10) ursodeoksikolik asit verilen diabetic fare grubu. Histopatolojik ve biyokimyasal deðerlendirmeler 4 hafta sonra kalp dokusundan yapýldý. Fibronektin ve TGF-β immunekspresyonu, TGF-β, malondialdehid, pentraxin-3, pro-BNP ve troponin-T düzeyleri ölçüldü.
BULGULAR: Fibronektin immunekspresyonu, TGF-β, pentraxin-3, troponin-t, pro-BNP ve malondialdehid düzeyleri diabetik farelerde control grubuna göre anlamlý olarak artmýþ saptandý. Ursodeoksikolik asidin inflamasyon belirteçlerini ve fibroz düzeyini anlamlý olarak azalttýðý izlendi
TARTIÞMA ve SONUÇ: Bu deneysel çalýþmada, ursodeoksikolik asidin diabetik farelerde anti-inflammatuar ve anti-fibrotik etkilerini gösterdik. Diabetik hastalarda ursodeoksikolik asidin ilaç olarak kullanýmý klinik olarak fayda gösterebilir.

Anahtar Kelimeler: diabetik kardiyomyopati, ursodeoksikolik asit, inflamasyon, kardiak fibroz

---

CITE